anaemia; chemotherapy‐induced anaemia; intravenous iron; iron deficiency; diagnosis; erythropoiesis‐stimulating agents
Abstract :
[en] Purpose – Patients with cancer frequently experience chemotherapy‐induced anaemia (CIA) and iron
deficiency (ID). Erythropoiesis‐stimulating agents (ESA), iron supplementation and blood transfusions are available therapies. This study evaluated routine practice in CIA management.
Methods – Medical oncologists and/or haematologists from nine European countries (n=375) were
surveyed on their last five cancer patients treated for CIA (n=1730). Information was collected on
tests performed at diagnosis of anaemia, levels of haemoglobin (Hb), serum ferritin and transferrin
saturation (TSAT), and applied anaemia therapies.
Results – Diagnostic tests and therapies for CIA varied across Europe. Anaemia and iron status were mainly assessed by Hb (94%) and ferritin (48%) measurements. TSAT was only tested in 14%. At anaemia diagnosis, 74% of patients had Hb ≤10g/dL, including 15% with severe (Hb <8g/dL) anaemia.
Low iron levels (ferritin ≤100ng/mL) were detected in 42% of evaluated patients. ESA was the most
commonly used treatment (63%) and 30% of ESA‐treated patients also received iron supplementation. Most iron‐treated patients (74%) received an oral iron; intravenous iron was
administered to 26%. 52% of patients received transfusions and in 76% of these, transfusions formed part of a regular anaemia treatment regimen. Management practices were similar in 2009 and 2011.
Conclusion – Management of anaemia and iron status in patients treated for CIA varies substantially
across Europe. Iron status is only assessed in half of the patients. In contrast to clinical evidence, iron treatment is underutilised and mainly based on oral iron supplementation. Implementation of
guidelines needs to be increased, particularly the minimisation of blood transfusions.
Disciplines :
Hematology
Author, co-author :
Ludwig, Heinz P.
Aapro, Matti S.
Bokemeyer, Carsten
Glaspy, John A.
Hedenus, Michael
Littlewood, Tim James
Osterborg, Anders C.
Rzychon, Beate
Mitchell, Daniell
BEGUIN, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia
Publication date :
2014
Journal title :
Supportive Care in Cancer
ISSN :
0941-4355
eISSN :
1433-7339
Publisher :
Springer Science & Business Media B.V., New York, United States - New York
Ludwig H, Van BS, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P et al (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293-2306 (Pubitemid 39348881)
Ludwig H, Muldur E, Endler G, Hubl W (2013) Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 24:1886-1892
Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB et al (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95:888-895 (Pubitemid 34839682)
Grotto HZ (2008) Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol 25:12-21
Aapro M, Osterborg A, Gascon P, Ludwig H, Beguin Y (2012) Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of intravenous iron. Ann Oncol 23:1954-1962
Beguin Y (2002) Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 87:1209-1221
Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I (2013) Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol 161:639-648
Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875-2882 (Pubitemid 32538197)
Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865-2874 (Pubitemid 32538196)
Ludwig H, Aapro M, Bokemeyer C, MacDonald K, Soubeyran P, Turner M, Albrecht Tet al (2009) Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer 45:1603-1615
Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M et al. (2009) Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data. Cochrane Database Syst Rev:CD007303
Spahn DR, Moch H, Hofmann A, Isbister JP (2008) Patient blood management: the pragmatic solution for the problems with blood transfusions. Anesthesiology 109:951-953
Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH (2008) Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 168:2377-2381
National Comprehensive Cancer Network Inc (2014) NCCN practice guidelines in oncology: cancer and chemotherapy-induced anemia - v.2. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp#supportive (28 August 2013, date last accessed).
Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Osterborg A, Repetto L et al (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43:258-270 (Pubitemid 46127840)
Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL et al (2010) American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 116:4045-4059
Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13(Suppl 3):33-36
Mikhael J, Melosky B, Cripps C, Rayson D, Kouroukis CT (2007) Canadian supportive care recommendations for the management of anemia in patients with cancer. Curr Oncol 14:209-217
Dirix L, Awada D, Bron D, Canon JL, De Grève J, Humblet Y, Peeters M et al (2010) Practice guidelines on the use of erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia. Belg J Med Oncol 4:57-64
Schrijvers D, De SH, Roila F (2010) Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 21(Suppl 5):v244-v247
Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S et al (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22:1301-1307 (Pubitemid 41079845)
Auerbach M, Silberstein PT, Webb RT, Averyanova S, Ciuleanu TE, Shao J, Bridges K (2010) Darbepoetin alfa 300 or 500 ug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 85:655-663
Bastit L, Vandebroek A, Altintas S, Gaede B, Pinter T, Suto TS, Mossman TWet al (2008) Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 26:1611-1618
Hedenus M, Birgegard G, Nasman P, Ahlberg L, Karlsson T, Lauri B, Lundin J et al (2007) Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 21:627-632 (Pubitemid 46444544)
Henry DH, Dahl NV, Auerbach M, Tchekmedyian S, Laufman LR (2007) Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 12:231-242
Pedrazzoli P, Farris A, Del PS, Del GF, Ferrari D, Bianchessi C, Colucci G et al (2008) Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 26:1619-1625
Gafter-Gvili A, Rozen-Zvi B, Vidal L, Leibovici L, Vansteenkiste J, Gafter U, Shpilberg O (2013) Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials. Acta Oncol 52:18-29
Beguin Y, Maertens J, De PB, Schots R, Seidel L, Bonnet C, Hafraoui K et al. (2013) Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. Am J Hematol
Bailie GR, Horl WH, Verhof JJ (2011) Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America. Drug Res 61:267-275
Geisser P (2009) The pharmacology and safety profile of ferric carboxymaltose (Ferinject®): structure/reactivity relationships of iron preparations. Port J Nephrol Hypert 23:11-16
Anker SD, Comin CJ, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF et al (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361:2436-2448
Kidney disease: Improving global outcomes (KDIGO) anemia work group (2012) KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney inter, Suppl 2:279-335
Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, Stella PJ et al (2011) Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 29:97-105
Steensma DP, Sloan JA, Loprinzi CL (2011) Reply to M. Aapro et al J Clin Oncol 29:e527-e528
Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H et al (2013) Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 24:475-482
Kim YT, Kim SW, Yoon BS, Cho HJ, Nahm EJ, Kim SH, Kim JH et al (2007) Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol 105:199-204 (Pubitemid 46441460)
Dangsuwan P, Manchana T (2010) Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol 116:522-525
Athibovonsuk P, Manchana T, Sirisabya N (2013) Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol 131:679-682
Hedenus M, Karlsson T, Ludwig H, Felder M, Roubert B, Birgegard G (2013) Intravenous ferric carboxymaltose as sole anemia therapy in patients with lymphoid malignancies, chemotherapy-induced anemia and functional iron deficiency. ASH Annual Meeting Abstracts. 3439 (poster)
Schrijvers D (2011)Management of anemia in cancer patients: transfusions. Oncologist 16(Suppl 3):12-18
Hofmann A, Farmer S, Shander A (2011) Five drivers shifting the paradigm from product-focused transfusion practice to patient blood management. Oncologist 16(Suppl 3):3-11
Spielmann M, Luporsi E, Ray Coquard I, De BS, Azria D, Lasocki S, Lafuma A et al (2012) Diagnosis and management of anaemia and iron deficiency in patients with haematological malignancies or solid tumours in France in 2009-2010: the AnemOnHe study. Eur J Cancer 48:101-107
Link H, Schmitz S (2013) Treatment of cancer-associated anaemia: results froma two-day cross-sectional survey in Germany. Onkologie 36:266-272
